(As of 9/30/2024)

TD China Income and Growth Fund - Investor Series

(Greater China Equity)

FundGrade A+^® Rating recipient
For more information about FundGrade click here

Inception Return (1/4/1994)	2.98 %
YTD Return	23.74 %

NAVPS (10/9/2024)	$24.38
Change	($1.64) / -6.30 %

Growth of $10,000 (As of September 30, 2024)

MER	2.65 %
Assets ($mil)	$195.24
Rank (1Yr)	65/67
Std Dev (3Yr)	15.45 %
Volatility Ranking (3Yr)	10/10
RRSP Eligibility	Yes
Load	No Load
Max Front End	-
Max Back End	-
Sales Status	Open

Objective

The fundamental investment objective is to seek to earn dividend income and to generate long term capital appreciation by investing primarily in equity securities of issuers located in China. The fundamental investment objective may only be changed with the approval of a majority of unitholders, given at a meeting called for that purpose.

Fund Manager

TD Asset Management Inc.

Portfolio Manager

Dino Vevaina, TD Asset Management Inc.

Sub-Advisor

Data not available

Asset Allocation
(As of September 30, 2024)

Sector Allocation
(As of September 30, 2024)

Geographic Allocation
(As of September 30, 2024)

Top 10 Holdings

Name	Asset	Sector	Geographic	Percent
Haier Smart Home Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	4.57%
Fuyao Glass Industry Group Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	4.50%
China Merchants Bank Co Ltd Cl A	International Equity	Financial Services	Asia/Pacific Rim	4.40%
Midea Group Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	4.37%
Byd Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	4.14%
Bank of Chengdu Co Ltd Cl A	International Equity	Financial Services	Asia/Pacific Rim	4.11%
Shenzhen Transsion Holdings Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	4.09%
Bank of Jiangsu Co Ltd Cl A	International Equity	Financial Services	Asia/Pacific Rim	4.02%
Kweichow Moutai Co Ltd Cl A	International Equity	Consumer Goods	Asia/Pacific Rim	3.80%
China Res Sanjiu Medical Pharma Co Ltd - Comn Cl A	International Equity	Healthcare	Asia/Pacific Rim	3.64%

Performance Data (As of September 30, 2024)

	Return (%)				Annualized Return (%)
Return	1 Mth	3 Mth	6 Mth	YTD	1 Yr	3 Yr	5 Yr	10 Yr
Fund	22.02	15.09	17.22	23.74	11.26	-6.02	2.69	4.80
Benchmark	23.51	19.03	13.77	11.97	7.48	-6.85	2.49	3.49
Quartile Ranking	1	2	3	2	4	2	2	4

Calendar Return (%)	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Fund	-18.05	-24.85	7.67	31.59	8.38	-7.29	28.05	1.43	12.72	4.25
Benchmark	-12.56	-21.94	7.65	26.06	25.82	-27.74	5.92	-22.11	39.34	56.37
Quartile Ranking	4	4	1	3	4	2	4	1	3	4

Website powered by © Fundata Canada Inc.
Mutual Fund Data provided by Fundata. | View Terms and Conditions of Use.
BofA Merill Lynch Indices used with permission.
© 2024 Fundata Canada Inc. All rights reserved. | View Privacy Policy | Contact Us.